Talent one indian pharma updates june 2015

http://www.ibef.org/industry/pharmaceutical-india/

showcase

IntroductionThe Indian pharmaceuticals market is third largest in terms of volume and thirteen largest in terms of value, as per a pharmaceuticals sector analysis report by equity master. The market is dominated majorly by branded generics which constitute nearly 70 to 80 per cent of the market. Considered to be a highly fragmented industry,consolidation has increasingly become an important feature of the Indian pharmaceutical market.India has achieved an eminent global position in pharma sector. The country also has a huge pool of scientists and

Website: http://www.talentone.in

Headquarters: TalentOne.In, 4th Floor, YSR Mansion, Sarjapur Road, Near HDFC Bank, Bangalore-560035, Karnataka, India

http://www.talentone.in/

http://www.ibef.org/industry/pharmaceutical-india/showcase



engineers who have the potential to take the industry to a very high level.The UN-backed Medicines Patents Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-AIDS medicine Tenofovir Alafenamide (TAF) for 112 developing countries.

Market SizeThe Indian pharmaceutical industry is estimated to grow at 20 per cent compound annual growth rate (CAGR) over the next five years, as per India Ratings, a Fitch Group company. Indian pharmaceutical manufacturing facilities registered with US Food and Drug Administration (FDA) as on March 2014 was the highest at 523 for any country outside the US.We expect the domestic pharma market to grow at 10-12 per cent in FY15 as compared to 9 per cent in FY14, as per a recent report from Centrum Broking. The domestic pharma growth rate was 11.9 per cent in October 2014, highlighted the report.Gujarat clocked the highest growth rate in pharmaceuticals market at 22.4 per cent during November 2014, surpassing the industry growth rate, which grew by 10.9 per cent, as per data from the market research firm AIOCD Pharma softtech AWACS.Also, growing at an average rate of about 20 per cent, India's biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics may reach the US$ 7 billion mark by the end of FY15, according to an industry body. Biopharma is the largest sector contributing about 62 per cent of the total revenue, with revenue generation to the tune of over Rs 12,600 crore (US$ 2.03 billion). The bio-pharma sector comprises vaccines, therapeutics and diagnostics.

InvestmentsThe Union Cabinet has given its approval to amend the existing FDI policy in the pharmaceutical sector in order to cover medical devices. The Cabinet has allowed FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to specified conditions.The drugs and pharmaceuticals sector attracted cumulative foreign direct investment (FDI) inflows worth US$ 12,813.02 million between April 2000 and December 2014, according to data released by the Department of Industrial Policy and Promotion (DIPP).Some of the major investments in the Indian pharmaceutical sector are as follows:Stelis Biopharma has announced the ground-breaking for construction of its customised, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's park and ecosystem for industrial and healthcare biotechnology at a total project investment amount of US$ 60 million.Pharma major Strides Arcolab has entered into a licensing agreement with US-based Gilead Sciences Inc to manufacture and distribute the latter's low-cost Tenofovir Alafenamide (TAF) product used for HIV treatment in developing countries. The licence to manufacture Gilead's low-cost drug extends to 112 countries.Apollo Hospitals Enterprise (AHEL) plans to add another 2,000 beds over the next two financial years, at a cost of around Rs 1,500 crore (US$ 242.57 million), as per Mr Prathap C Reddy, Founder and Executive Chairman, Apollo Hospitals.CDC, the UK’s development finance institution, has invested US$ 48 million in Narayana Hrudayalaya hospitals, a multi-speciality healthcare provider. With this investment, Narayana Health will expand affordable treatment in eastern, central and western India.Cadila Healthcare Ltd has announced the launch of a biosimilar for Adalimumab - the world’s largest selling drug for rheumatoid arthritis and other auto immune disorders. The drug will be marketed under the brand name Exemptia at one-fifth of the price for the branded version-Humira. Cadila’s biosimilar is the first to be launched by any company in the world and is a finger print match with the original in terms of safety, purity and potency of the product, as per the company.Torrent Pharmaceuticals has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India — Rituximab, Adalimumab and Cetuximab.Piramal Enterprises Ltd has acquired US-based Coldstream Laboratories for US$ 30.6 million in an all-cash transaction.Indian Immunologicals Ltd (IIL) plans to set up a new vaccine manufacturing facility in Pondicherry with an investment of Rs 300 crore (US$ 48.53 million).SRF Ltd has acquired Global DuPont Dymel, the pharmaceutical propellant business of DuPont, for US$ 20 million.

Government InitiativesThe Addendum 2015 of the Indian Pharmacopoeia (IP) 2014 is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health & Family Welfare, Government of India. The addendum would play a significant role in improving the quality of medicines which in turn promote public health and accelerate the growth and development of pharma sector.The Government of India has unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. It has reduced approval time for new facilities to boost investments. Further, the government has also put in place mechanisms such as the Drug Price Control Order and the National Pharmaceutical Pricing Authority to address the issue of affordability and availability of medicines.Romania is keen to tie up with the Indian pharmaceutical companies for research and develop new drugs. "Romania will collaborate with India for license acquisition to sale India's drugs in Europe," said Mr Mario Crute, Counselor in Ministry of health in Romania at GCCI. The country will tie up with the Indian pharmaceutical companies for research and develop new drugs.Some of the major initiatives taken by the government to promote the pharmaceutical sector in India are as follows:Indian and global companies have expressed 175 investment intentions worth Rs 1,000 crore (US$ 161.78 million) in




the pharmaceutical sector of Gujarat. The memorandums of understanding (MoUs) would be signed during the Vibrant Gujarat Summit.Telangana has proposed to set up India's largest integrated pharmaceutical city spread over 11,000 acres near Hyderabad, complete with effluent treatment plants and a township for employees, in a bid to attract investment of Rs 30,000 crore (US$ 4.85 billion) in phases. Hyderabad, which is known as the bulk drug capital of India, accounts for nearly a fifth of India's exports of drugs, which stood at Rs 90,000 crore (US$ 14.56 billion) in 2013-14.

Road AheadThe Indian pharma market size is expected to grow to US$ 85 billion by 2020. The growth in Indian domestic market will be on back of increasing consumer spending, rapid urbanisation, raising healthcare insurance and so on.Going forward, better growth in domestic sales will depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers are on the rise.Moreover, the government has been taking several cost effective measures in order to bring down healthcare expenses. Thus, governments are focusing on speedy introduction of generic drugs into the market. This too will benefit Indian pharma companies. In addition, the thrust on rural health programmes, life saving drugs and preventive vaccines also augurs well for the pharma companies.Exchange rate used INR 1= US$ 0.016 as on February 26, 2015References: Consolidated FDI Policy, Department of Industrial Policy & Promotion (DIPP), Press Information Bureau (PIB), Media Reports, Pharmaceuticals Export Promotion Council

Last Updated: March, 2015India is expected to be the third-largest global generic active pharmaceutical ingredient (API) merchant market by 2016,

with a 7.2 per cent market share. The country accounts for the second largest number of Abbreviated New Drug Applications (ANDAs) and is the world’s leader in Drug Master Files (DMFs) applications with the US.The country's pharmaceutical industry expanded at a compound annual growth rate (CAGR) of 9.4 per cent in 2013 to reach US$ 12 billion and is expected to expand at a CAGR of 23.9 per cent to US$ 55 billion by 2020. With 72 per cent of market share, generic drugs form the largest segment of the Indian pharmaceutical sector.In terms of value, exports of pharmaceutical products from India increased at a CAGR of 26.1 per cent to US$ 10.1 billion during FY06–13. Generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years.The Government of India plans to set up a US$ 640 million venture capital fund to boost drug discovery and strengthen pharma infrastructure. Pharma Vision 2020 by the government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery.With 70 per cent of India’s population residing in rural areas, pharma companies have immense opportunities to tap this market. Various companies are investing in the distribution network in rural areas. India also has the potential to attract huge investments to its clinical trial market.




Sun Pharma scouting for more deals; may spend $7bn

India's Sun Pharmaceuticals Industries Ltd, emboldened by its takeover of domestic rival Ranbaxy Laboratories, is willing to spend as much as $7 billion on further acquisitions, bankers familiar with the generic drugmaker's strategy

said.

The just completed Ranbaxy deal, its biggest to date at $3.2 billion, has given India's biggest drugmaker sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products

and gaining a bigg ..

Read more at:http://economictimes.indiatimes.com/articleshow/47083282.cms?

utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

CCI imposes penalty on pharma majors GlaxosmithKline and

Sanofi India Read more at:

http://economictimes.indiatimes.com/articleshow/47557311.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Competition Commission has imposed a penalty of Rs 64 crore on drugmakers GlaxoSmithKline Pharmaceuticals and Sanofi for collusive bidding in supply of a meningitis vaccine to the government for Haj pilgrims.

The matter relates to supply of polysaccharide Quadrivalent Meningococcal Meningitis (QMMV) vaccines and the complaint was filed by Bio-Med Pvt Ltd, which also makes this drug. The complaint was also filed against the Health

and Family Welfare Ministry.ADVERTISING

Every year, the government invites tenders for purchase of meningitis vaccine that is required to be administered

upon Haj pilgrims.Apart from imposing penalties, the Commission has directed GlaxoSmithKline and Sanofi to "cease and desist" from

anti-competitive practices.A fine of Rs 60.45 crore has been slapped on GlaxoSmithKline and Rs 3.04 crore on Sanofi, the Competition

Commission of India (CCI) said.

Cipla gets USFDA approval for child-friendly HIV drug delivery

system




Indian pharma industry is one of the biggest considering a

population of over 1.2 billion to be served. Companies have been consistently investing crores of rupees every year to serve the best medication to the people.

Here is a list of the top 10 pharmaceutical companies in

India in 2014, which are ranked on the basis of their sales

revenueTop 10 Indian Pharma companies by sales revenue-

10. Wockhardt

Wockhardt Ltd. is an Indian pharma company. Its headquarters are located in Mumbai, India. It was founded by Habil Khorakiwala in the early 1960s from the acquisition of Worli Chemical Works in 1959, incorporated as Wockhardt Pvt. Ltd., in 1973 and then as Wockhardt Ltd. in1999. Wockhardt has presence globally with its presence in Russia, Uganda, Brazil, Kenya, Mexico, Vietnam, Ghana, Mauritius, Philippines, Nigeria, Nepal, Tanzania, Myanmar, Sri Lanka, Lebanon and Kuwait. UK, followed by US is the biggest market

9. GlaxoSmithKline

GSK is a British pharma and consumer healthcare company. Its headquarters are located in Brentford, London. The company was founded by the merger of Glaxo Wellcome and SmithKline Beecham plc in 2000. It has employee strength of over 99,000 worldwide. The company produces drugs and vaccines for diseases like asthma, diabetes, cancer, infections, digestive and mental health conditions. The blockbuster drugs of GSK are Advair, Avodart, Flovent, Augmentin, Lovaza, and

8. Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd. is an Indian pharma company. Its headquarters are based in Ahmedabad. It was founded by U.N. Mehta with the name of Trinity Laboratories Ltd. It has employee strength of 4000 across the world. Torrent Pharmaceuticals operates in more than 50 countries with over 1000 products. It has 7 fully owned subsidiaries in Germany , US, Russia, Phillippines, Brazil and Canada. The company operates in the following key areas: APIs, Formulations, Discovery, Marketing and Sales of Drugs. The Company was the first to launch ranitidine (Ranitin), atenolol (Betacard) ,




for Wokhardt. Wokhardt produces formulations, biopharmaceuticals, nutrition products,vaccines and active pharmaceutical ingredients (APIs). It has employee strength of 7900 on a global scale. Wockhardt Hospitals is a subsidiary of the Wockhardt Group. Wockhardt’s blockbuster drug is Toprol which is used to treat hypertension. Some of the key drugs are Flonase, nasal spray to treat congestion, Stalevo, used to treat Parkinson's disease, Comtan, Another drug to treat Parkinson's.

Sales Revenue: Rs. 2471.18 cr.

Lamictal. The consumer healthcare division of GSK includes nutritional products and drinks like Boost and Horlicks, over-the-counter (OTC) medicines and oral healthcare products like Sensodyne. GSK has announced that it will only pay fees to doctors for critical functions that help obtain insights into specific diseases like company sponsored scientific advisory services, clinical trials and market research.


nifedipine (Calcigard), domperidone (Domstal), amiodorane (Cordarone), diltiazem (Dilzem), Lisinopril (Listril), etc. in the Indian market. The Company is a leader in the Cardiovascular segment. It is the third in the industry in Gastro-Intestinal Drugs segment. Torrent Pharma launched, the world’s first ‘polypill’ CVpill, in Cardiac care. The company launched India’s first Rimonabant called Rimoslim. It was also the first to launch India’s first bulk laxative in tablet form (Fibotab).


7. Ipca laboratoriesIpca Laboratories is an Indian pharma company. Its headquarters are located in Mumbai, India. It was founded by K.B. Mehla and Dr. N.S. Tibrawala along with a group of others including mediacl professionals and businessmen in 1949. Later, in 1975, the company was taken over by Amitabh Bachchan, Jaya Bachchan, Ajitabh Bachchan, P.C. Godha and M.R. Chandurkar. Ipca Labs has an employee base of 8000 across 36 countries. It is one of the largest suppliers of APIs. It manufactures more than 150 drugs that include tablets, capsules, oral liquids and dry powders. The company manufactures many kinds of drug intermediates including Acetylthiophene, Theo bromine and P- Bromo Toluene. The company is mainly involved in the production and marketing of pharmaceuticals such as drug intermediates, formulations, and active pharmaceutical ingredients (API).


6. Jubilant Life Sciences LimitedJubilant Life Sciences Limited is an Indian pharmaceutical and life sciences company. The company was incorporated as Vam Organic Chemicals Ltd. in 1978. It has a presence in over 100 countries with ground presence in India, North America, Europe and China. It has an employee base of around 6200. Jubilant Life Sciences manufactures and supplies APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients, and provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development.


5. Cadila HealthcareCadila Healthcare is an Indian pharma company. Its headquarters are located at Ahmedabad, Gujarat, India. Cadila Laboratories was founded by Ramanbhai Patel and Shri Indravadan Modi in 1952. The company has employee strength of over 11000 across the world. In 1995 Cadila Healthcare came under the Patel family and Cadila Pharmaceuticals Ltd. came under the Modi family, following the split of the two families. The company develops and manufactures

4. Aurobindo Pharma Ltd.Aurobindo Pharma Limited is an Indian pharma and manufacturing company. Its headquarters are located in Hyderabad, India with a market base of over 125 countries. It manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs) mainly for six major therapeutic/product areas: antibiotics, gastroenterologicals, anti-retrovirals, cardiovascular products, anti-allergics and central nervous system products. The company also has a presence in the manufacture of anti-diabetics and

3. Lupin Limited Lupin Limited is an Indian pharma company based in Mumbai. The company’s R&D headquarters are located at the Lupin Research Park, near Pune with more than 1200 scientists. It has employee base of 11355. It is also the fastest growing generic pharmaceutical company in Japan and the US, the two largest pharmaceutical markets of the world. It is also the 5th largest and the fastest growing generic pharmaceutical player in South Africa. Lupin was in Dr.




pharmaceutical as well as diagnostic products, skin care products, herbal products, and other OTC products. The various therapeutic segments covered by Cadila Healthcare are Anti-Infective, Anti-Allergic, Anti-Epileptic, Anti-Osteoporosis, Anti-Depressant, Gastrointestinals, Sedative, Women’s Healthcare, Anti-Rheumatic, Tranquilizers, Anti-Diabetic, Anti-Psychotic, Pain Management and Tadalafil. The blockbuster drugs are Oflin OD, Clodus, Zoldac, NeoLoridin, Ven-OD, Isbis, Bonmax, Mexate, Cartup, Zyqin, Oxeptal, Zytonin, Cefinar, Zycolchin, Vageston, Xet, Espra, Aldren, Serlin, Epsolin, Euglim, Olandus, Divalpro, Topiram, Cytolog, Stilnite, Mifegest, Dactive, Linid, Mosadac, Salazar, Lamidus, and Zydalis.


cephalosporins. Aurobindo Pharma started with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry, in in 1988-89 and is the market leader in Semi-Synthetic Penicillin today. Some of the products are Raloxifene, Atazanavir, Aliskiren, Fumerate, Montelukast and Amoxycillin Trihydrate. Sales Revenue: Rs. 5425.1 cr.

D.B. Gupta founded in 1968. Lupin is one of the largest manufacturers of TB drugs. The company has a presence in the Cardiovascular, Anti-Infectives, Asthma, Diabetology, Pediatrics, GI, CNS and NSAIDs therapy segments. It is also a leader in the Cephalosporin segment. Lupin’s business areas are branded and generic formulations, advanced drug delivery systems to biotechnology and APIs. Lupin has a presence in more than 70 countries in markets like USA, Australia, South Africa, Japan, Europe, India and the Philippines.


2. Cipla LimitedCipla Limited is an Indian pharma company. Its headquarters are located in Mumbai, India. It was founded in 1935 by Dr. K. A. Hamied. It was originally name as 'The Chemical, Industrial & Pharmaceutical Laboratories' and later condensed as Cipla in 1984 from the initials of each word in the name. The company has an employee base of 27,562 worldwide. It has 34 manufacturing units in India and a global presence spanning 170 countries. The company offers over 2000 products in around 65 therapeutic categories, in more than 40 dosage forms. Cipla also has a hospice called the 'Cipla Palliative Care and Training Centre' located in Pune, for terminally ill cancer patients. Through this hospice, Cipla claims to have provided medicines and medical services to 8,500 patients till date totally free of cost. Cipla has a presence in treatment areas that include cardiovascular disease, respiratory, weight control, diabetes, urology, musculoskeletal, neuropsychiatry, oncology, HIV-AIDS, allergy, anti-infectives, analgesic, anti malarial, dermatology and cosmeceuticals, gastroenterology, iron chelators, nutritional and ophthalmic products, hormones and steroids, and women’s health etc.. Cipla is the first pharma company to manufacture the

1. Dr.Reddy’s LabDr. Reddy's Laboratories Ltd. is an Indian pharma company. Its headquarters are located in Andhra Pradesh, India. Dr. Reddy’s Labs was founded by Anji Reddy. The company produces and sells pharmaceuticals in the form of over 190 medications and 60 APIs in India and overseas. It has employee strength of 16,300 worldwide. Some of the major APIs of Dr.Reddy’s are Ibuprofen, Naproxen, Sparfloxacin etc. Some of the major brands of drugs of the company are Mintop, Atocor, Stamlo and Reclimet.

Sales Revenue: Rs. 8434 cr.




world’s first oral iron chelator – by the name of Deferiprone. Cipla also has a presence in the veterinary and pet-care segment. The main products in the company’s portfolio are Lamivudine, Escitalopram (anti-depressant) and Fluticasone propionate.Sales Revenue: Rs. 8202.42 cr.




TalentOne TEAM

Our Analysts are careerists in search business; we built a team of experts who create everyday value to clients in meeting their talent strategy.

Industry Expert Advisors: We Keep interviewing industry experts to gather key information and latest trends in different industry, technology and business operations. We also consult with a high-value panel of experts on some of our prized mandates. We are a vertically integrated talent search and selection company

NEERAJ KUMARFounder & CEONeeraj is an executive search enthusiast. An IIT Delhi graduate with rich global experience with firms like British Telecom and BEA Systems, delivering on-site technology solutions, Neeraj chose executive search as his next passion venture.He leads business and is responsible for building TalentOne, a world class search and selection firm.

Email – [email protected] – in.linkedin.com/in/neekum

MRINAL KRANTSearch Practice Partner-Pharma|Medical Device| Drug Safety-Technology-India and US More than 8 years into Pharma Consulting, Technology, Drug Safety and Device hiring. Mrinal is a talent connoisseur, passionate about resolving mystery of talent selection. He plays this alchemist role as his dream to create an enviable search practice in ever enigmatic world of hiring. Mrinal has an MBA from Symbiosis Institute of Business Management and close to a decade of learning and experimenting with facts and myths of human resources applications. Schneider Electric’s APC and ZS Associates are a few companies he worked for.

Email – [email protected] – in.linkedin.com/pub/mrinal-krant/6b/9b/938


